This increased expression of both PD-1 and PD-L1 made these tumours more responsive to checkpoint inhibitors by inhibiting the PD-1/PD-L1 interaction and improving the ability of host immune cells to kill the tumour cells. Here, CD274 is linked to neoplasm.